GSK,SNY,TEVA -

. Currency in USD
Stock chart is not supported by your current browser
Previous CloseN/A
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52 Week Rangeundefined - undefined
VolumeN/A
Avg. VolumeN/A
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Theravance Shares Rise on Approval of Glaxo's COPD Therapy
    Zacks4 hours ago

    Theravance Shares Rise on Approval of Glaxo's COPD Therapy

    Theravance Biopharma's (TBPH) shares traded up as investors cheered the potential cash flows related to future sales of recently approved Glaxo's triple combination COPD therapy.

  • Glaxo's Triple Therapy COPD Inhaler Gets Marketing Nod in EU
    Zacks5 hours ago

    Glaxo's Triple Therapy COPD Inhaler Gets Marketing Nod in EU

    Glaxo (GSK) and partner Innoviva announced that their triple combination therapy, Trelegy Ellipta, was granted marketing authorization in the EU as maintenance therapy for the treatment of patients with COPD.

  • Investopedia7 hours ago

    John Paulson 13F: Exited Facebook, Took New Stakes In Q3

    John Paulson's hedge fund made sweeping changes to its holdings in the third quarter.

  • Capital Cube8 hours ago

    ETFs with exposure to Teva Pharmaceutical Industries Ltd. : November 17, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Teva Pharmaceutical Industries Ltd. Here are 5 ETFs with the largest exposure to TEVA-US. Comparing the performance and risk of Teva Pharmaceutical Industries Ltd. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower ... Read more (Read more...)

  • SmarterAnalyst11 hours ago

    Mizuho Wonders if Teva Can Avoid Downgrade to High Yield After Rocky 3Q Print

    Can Teva Pharmaceutical (NYSE:TEVA) recover after such a third quarter earnings fall? Mizuho analyst Irina Rivkind Koffler is left asking questions of whether the company will face a downgrade to high yield or whether it can find the "transformative deal" needed for a core generics comeback. Next year looks possible for recovery, but what of Teva's long-term revival?

  • Alnylam Starts Rolling NDA Submission for RNAi Candidate
    Zacks12 hours ago

    Alnylam Starts Rolling NDA Submission for RNAi Candidate

    Alnylam (ALNY) has started rolling New Drug Application to the FDA for its RNAi candidate, patisiran.

  • Market Realist13 hours ago

    Taking a Deeper Look at Antares Pharma’s Financials in 2017

    Antares Pharma’s gross profit margins reached 45.0%, 57.0%, and 58.0% for fiscal 2016, fiscal 2015, and fiscal 2014, respectively.

  • Teva Pharmaceutical Industries Limited (TEVA) Is Trading At A 48.87% Discount To Its Intrinsic Value
    Simply Wall St.yesterday

    Teva Pharmaceutical Industries Limited (TEVA) Is Trading At A 48.87% Discount To Its Intrinsic Value

    Does the share price for Teva Pharmaceutical Industries Limited (NYSE:TEVA) reflect it’s really worth? Today, I will calculate the stock’s intrinsic value using the discounted cash flow (DCF) method. AnyoneRead More...

  • SmarterAnalystyesterday

    Billionaire Israel “Izzy” Englander Bets on Troubled Pharma Giants Teva and Valeant, Nixes Acadia

    Billionaire Israel "Izzy" Englander, who helmed his fortune from humble, Polish immigrant beginnings took a chance on two giants that have played with volatile fire in the market: Teva Pharmaceutical (NYSE:TEVA) and Valeant Pharmaceuticals (NYSE:VRX). However, the hedge fund guru is doing away with almost all of ACADIA Pharmaceuticals (NASDAQ:ACAD), a stock that has attracted mostly bullish attention on the Street.

  • Market Realistyesterday

    AstraZeneca’s Valuation after 3Q17 Earnings

    In 3Q17, AstraZeneca reported EPS of $0.56 on revenues of $6.2 billion compared to estimates of $0.71 for EPS on revenues of $6 billion.

  • Market Realistyesterday

    Exploring Antares Pharma’s Current Pipeline of Products

    On October 11, 2017, Antares Pharma (ATRS) was notified by the FDA that it had found deficiencies in Xyosted.

  • Market Realistyesterday

    How Did Sanofi Pasteur Perform in 3Q17?

    Sanofi Pasteur reported revenues of 1.92 billion euros for 3Q17, which was 11% higher YoY (year-over-year) at constant exchange rates.

  • Market Realist2 days ago

    Behind Novartis’s Entresto and Gilenya Performances in 3Q17

    In 3Q17, Novartis's (NVS) Entresto generated revenues of $128 million, compared with $53 million in 3Q16. Entresto witnessed a ~16% rise on a QoQ basis.

  • Market Realist2 days ago

    Behind Sanofi’s Generics and Consumer Healthcare Business in 3Q17

    Sanofi's generics business reported revenues of 433 million euros for 3Q17—a 0.9% YoY (year-over-year) fall.

  • Reuters2 days ago

    Europe approves GlaxoSmithKline's new triple lung drug

    Europe has approved GlaxoSmithKline's (GSK.L) new three-in-one inhaler for chronic lung disease, which the group hopes will help it keep its lead in respiratory medicine despite falling sales of older drug Advair. Trelegy Ellipta is the first once-daily triple medicine for chronic obstructive pulmonary disease (COPD), putting GSK ahead of rivals such as AstraZeneca (AZN.L) and Novartis (NOVN.S). The decision by the European Commission to grant it marketing authorisation, announced by the company on Thursday, had been expected following a positive recommendation from the European Medicines Agency in September.

  • Moody's2 days ago

    Health and Happiness (H&H) Int'l. Hldgs. Ltd. -- Moody's: Health and Happiness' ratings unaffected by Swisse's buy-back of distribution rights

    Announcement: Moody's: Health and Happiness' ratings unaffected by Swisse's buy-back of distribution rights. Global Credit Research- 16 Nov 2017. Hong Kong, November 16, 2017-- Moody's Investors Service ...

  • Reuters2 days ago

    Europe approves GlaxoSmithKline's new triple lung drug

    Europe has approved GlaxoSmithKline's new three-in-one inhaler for chronic lung disease, which the group hopes will help it keep its lead in respiratory medicine despite falling sales of older drug Advair. Trelegy Ellipta is the first once-daily triple medicine for chronic obstructive pulmonary disease (COPD), putting GSK ahead of rivals such as AstraZeneca and Novartis. The decision by the European Commission to grant it marketing authorisation, announced by the company on Thursday, had been expected following a positive recommendation from the European Medicines Agency in September.

  • The Wall Street Journal2 days ago

    [$$] Gates Foundation, Abu Dhabi Pair to Fight Forgotten Diseases

    The Crown Prince of Abu Dhabi launched a fund with the Bill & Melinda Gates Foundation to eliminate river blindness and lymphatic filariasis, which leads to a condition known as elephantiasis.

  • Why The Children's Place, Teva Pharmaceutical Industries, and Sears Holdings Jumped Today
    Motley Fool2 days ago

    Why The Children's Place, Teva Pharmaceutical Industries, and Sears Holdings Jumped Today

    Get the scoop on what sent these stocks higher.

  • Barrons.com2 days ago

    Will Teva's Pipeline Lead It to the Promised Land?

    Shares of generic and specialty drug producer Teva  Pharmaceutical (TEVA) jumped 7% Wednesday afternoon as investors get more hopeful about the future. Jefferies analysts met with Teva executives in Israel including the head of research and development, and concluded in a fresh report today that new CEO Kare Schultz may discuss strategy with investors by the end of the year, to coincide with quarterly results. Jefferies analysts David Steinberg, Edward Chung and Anthony Baldor gleaned in meetings that cost cutting and asset sales are "on the table" for Teva, with $35 billion in debt, high leverage and weakening profitability over time.

  • Despite Valeant Improvement, VRX Stock Price Is Still Too High
    InvestorPlace2 days ago

    Despite Valeant Improvement, VRX Stock Price Is Still Too High

    New CEO Joe Papa has done a nice job in his efforts to turn around Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Generic drugmakers have been taken to the woodshed, with Teva Pharmaceutical Industries Ltd (NYSE:TEVA) down 67% year-to-date and Mallinckrodt PLC (NYSE:MNK) off 56%.

  • Benzinga2 days ago

    VBI Vaccines Could Nearly Triple In Value On New Drug Launches, According To BMO

    VBI Vaccines, Inc. - Ordinary Shares (NASDAQ: VBIV ) will release results on three clinical trials in the first half of 2018, presenting certain investment opportunities of an uncertain nature. Some on ...

  • The Wall Street Journal2 days ago

    [$$] Foundation Consumer Healthcare Buys Plan B One-Step From Teva

    In support of the $675 million deal, Greg Bradley joined Foundation Consumer Healthcare as president and chief executive.

  • SmarterAnalyst2 days ago

    Cantor Continues to Play It Cautious on Teva Following Management Meeting

    Teva Pharmaceutical (NYSE:TEVA) has a few loose ends untied, from generics pressures to brand drug launches and pipelines that still need to prove themselves, before the Israeli pharma giant can make a comeback- at least in the eyes of Cantor analyst Louise Chen.

  • GE among IQ100 leaders
    CNBC Videos2 days ago

    GE among IQ100 leaders

    The CNBC IQ100 index beating the broader market over one year, up 22%. Today's leaders include GE, Teva pharma and Nike. The laggards Target, Johnson Controls and Mattel